evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

51 questions · 51 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 5.9%GRADE not reported 10 · 19.6%Very low 11 · 21.6%Low 17 · 33.3%Moderate 10 · 19.6%High 0 · 0%

RISPERIDONE DEPOT vs placebo

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ all doses risperidone depot ‐… compared with PLACEBO (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs placebo

Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term Spontaneous reporting by study participants · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General: Severe adverse event ‐ any dose risperidone… compared with PLACEBO (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs placebo

Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific: Weight gain ‐ all doses of depot… compared with PLACEBO (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review